Limits...
Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis.

Zhao S, Wu D, Wu P, Wang Z, Huang J - PLoS ONE (2015)

Bottom Line: Pooled data were weighted using the Mantel-Haenszel Fixed-effect model.High level of serum IL-10 was significantly associated with worse OS at 1-year (OR = 3.70, 95% CI = 2.81 to 4.87, P < 0.00001), 3-year (OR = 3.33, 95% CI = 2.53 to 4.39, P < 0.0001) and 5-year (OR = 2.80, 95% CI = 1.90 to 4.10, P < 0.0001) of cancer.High expression of serous IL-10 leads to an adverse survival in most types of cancer.

View Article: PubMed Central - PubMed

Affiliation: Cancer Institute (Key Laboratory of Cancer Prevention & Intervention, National Ministry of Education; Provincial Key Laboratory of Molecular Biology in Medical Sciences), Zhejiang University, Hangzhou, China; Department of Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.

ABSTRACT

Background: IL-10 is an important immunosuppressive cytokine which is frequently elevated in tumor microenvironment. Some studies have reported that overexpression of serous IL-10 is correlated with worse outcome in patients with malignant tumor. Here, we conducted a meta-analysis to assess the prognostic impact of serous IL-10 expression in cancer patients.

Methods: We searched PubMed and EBSCO for studies in evaluating the association of IL-10 expression-in serum and clinical outcome in cancer patients. Overall survival (OS) was the primary prognostic indicator and disease-free survival (DFS) was the secondary indicator. Extracted data were computed into odds ratios (ORs) and 95% confidence interval (CI) or a P value for survival at 1, 3 and 5 years. Pooled data were weighted using the Mantel-Haenszel Fixed-effect model. All statistical tests were two-sided.

Results: A total of 1788 patients with cancer from 21 published studies were incorporated into this meta-analysis. High level of serum IL-10 was significantly associated with worse OS at 1-year (OR = 3.70, 95% CI = 2.81 to 4.87, P < 0.00001), 3-year (OR = 3.33, 95% CI = 2.53 to 4.39, P < 0.0001) and 5-year (OR = 2.80, 95% CI = 1.90 to 4.10, P < 0.0001) of cancer. Subgroup analysis showed that the correlation between serous IL-10 expression and outcome of patients with solid tumors and hematological malignancies are consistent. The association of IL-10 with worse DFS at 1-year (OR = 3.34, 95% CI = 1.40 to 7.94, P = 0.006) and 2-year (OR = 3.91, 95% CI = 1.79 to 8.53, P = 0.0006) was also identified.

Conclusions: High expression of serous IL-10 leads to an adverse survival in most types of cancer. IL-10 is a valuable biomarker for prognostic prediction and targeting IL-10 treatment options for both solid tumors and hematological malignancies.

No MeSH data available.


Related in: MedlinePlus

Forest plots describing odds ratios of the association between serous interleukin–10 (IL–10) expression and disease-free survival (DFS) at 1 year and 3 years.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4595202&req=5

pone.0139598.g006: Forest plots describing odds ratios of the association between serous interleukin–10 (IL–10) expression and disease-free survival (DFS) at 1 year and 3 years.

Mentions: A total of 3 studies reported data for DFS at 1 year and 2 years. Results showed that IL–10 overexpression was associated with worse 1-year DFS (OR = 3.34, 95% CI = 1.40 to 7.94, P = 0.0006) and worse 2-year DFS (OR = 3.91, 95% CI = 1.79 to 8.53, P = 0.0006) of cancer. There was no significant heterogeneity among studies (1 year: Cochran’s Q P = 0.44, I2 = 0%; 2 years: Cochran’s Q P = 0.60, I2 = 0%) (Fig 6).


Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis.

Zhao S, Wu D, Wu P, Wang Z, Huang J - PLoS ONE (2015)

Forest plots describing odds ratios of the association between serous interleukin–10 (IL–10) expression and disease-free survival (DFS) at 1 year and 3 years.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4595202&req=5

pone.0139598.g006: Forest plots describing odds ratios of the association between serous interleukin–10 (IL–10) expression and disease-free survival (DFS) at 1 year and 3 years.
Mentions: A total of 3 studies reported data for DFS at 1 year and 2 years. Results showed that IL–10 overexpression was associated with worse 1-year DFS (OR = 3.34, 95% CI = 1.40 to 7.94, P = 0.0006) and worse 2-year DFS (OR = 3.91, 95% CI = 1.79 to 8.53, P = 0.0006) of cancer. There was no significant heterogeneity among studies (1 year: Cochran’s Q P = 0.44, I2 = 0%; 2 years: Cochran’s Q P = 0.60, I2 = 0%) (Fig 6).

Bottom Line: Pooled data were weighted using the Mantel-Haenszel Fixed-effect model.High level of serum IL-10 was significantly associated with worse OS at 1-year (OR = 3.70, 95% CI = 2.81 to 4.87, P < 0.00001), 3-year (OR = 3.33, 95% CI = 2.53 to 4.39, P < 0.0001) and 5-year (OR = 2.80, 95% CI = 1.90 to 4.10, P < 0.0001) of cancer.High expression of serous IL-10 leads to an adverse survival in most types of cancer.

View Article: PubMed Central - PubMed

Affiliation: Cancer Institute (Key Laboratory of Cancer Prevention & Intervention, National Ministry of Education; Provincial Key Laboratory of Molecular Biology in Medical Sciences), Zhejiang University, Hangzhou, China; Department of Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.

ABSTRACT

Background: IL-10 is an important immunosuppressive cytokine which is frequently elevated in tumor microenvironment. Some studies have reported that overexpression of serous IL-10 is correlated with worse outcome in patients with malignant tumor. Here, we conducted a meta-analysis to assess the prognostic impact of serous IL-10 expression in cancer patients.

Methods: We searched PubMed and EBSCO for studies in evaluating the association of IL-10 expression-in serum and clinical outcome in cancer patients. Overall survival (OS) was the primary prognostic indicator and disease-free survival (DFS) was the secondary indicator. Extracted data were computed into odds ratios (ORs) and 95% confidence interval (CI) or a P value for survival at 1, 3 and 5 years. Pooled data were weighted using the Mantel-Haenszel Fixed-effect model. All statistical tests were two-sided.

Results: A total of 1788 patients with cancer from 21 published studies were incorporated into this meta-analysis. High level of serum IL-10 was significantly associated with worse OS at 1-year (OR = 3.70, 95% CI = 2.81 to 4.87, P < 0.00001), 3-year (OR = 3.33, 95% CI = 2.53 to 4.39, P < 0.0001) and 5-year (OR = 2.80, 95% CI = 1.90 to 4.10, P < 0.0001) of cancer. Subgroup analysis showed that the correlation between serous IL-10 expression and outcome of patients with solid tumors and hematological malignancies are consistent. The association of IL-10 with worse DFS at 1-year (OR = 3.34, 95% CI = 1.40 to 7.94, P = 0.006) and 2-year (OR = 3.91, 95% CI = 1.79 to 8.53, P = 0.0006) was also identified.

Conclusions: High expression of serous IL-10 leads to an adverse survival in most types of cancer. IL-10 is a valuable biomarker for prognostic prediction and targeting IL-10 treatment options for both solid tumors and hematological malignancies.

No MeSH data available.


Related in: MedlinePlus